Subcutaneous Biologic Market

Subcutaneous Biologic Market Outlook (2024 to 2034)

The global subcutaneous biologic market is analyzed to reach a valuation of US$ 1.87 billion in 2024 and is further projected to touch US$ 5.41 billion by 2034-end. Demand is evaluated to expand at a CAGR of 11.2% between 2024 to 2034.

The need for biological medicines is driven by the increasing prevalence of chronic illnesses, such as diabetes, rheumatoid arthritis, and different types of cancer. Subcutaneous biologics provide efficient means of treating several conditions, promoting patient compliance, and enhancing health results. Self-administering therapies at home are becoming more popular among patients than ones that need hospital visits for intravenous infusions.

More comfort and convenience are made possible by subcutaneous delivery, which improves patient satisfaction and compliance. Pre-filled syringes, auto-injectors, and wearable technology are examples of innovations in drug delivery systems that have enhanced the efficacy, convenience, and safety of subcutaneous biologic administration.

North America is projected to account for 34.4% of the global market share in 2024. The market in North America is continuously showing bullish sentiments because of its strong healthcare system and high rate of chronic illness. Other than this, several biopharmaceutical companies and academic institutes that specialize in advanced biologic medicines are located in the region, which is further driving market expansion.

Based on indication, the cancer segment is analyzed to hold 33.4% of the overall market revenue in 2024 due to the increasing number of patients with different types of cancer and this is also driving up emphasis on new therapeutic approaches. Subcutaneous biologics, such as targeted treatments and monoclonal antibodies provide efficient substitutes for intravenous infusions in clinical settings, allowing patients to self-administer at home and improving patient compliance.

By delivery system, the syringe category is estimated to lead with 39.6% of the revenue share in 2024 because of its convenience of use, safety characteristics, and adaptability. Syringes are a desirable option for at-home self-administration of biologic medicines because of their well-known simple administration procedure.

Biologics are all pharmaceutical products developed using a biological process. Biologic products include drugs manufactured from various living organisms with the help of biotechnology. Subcutaneous biologics consists of sugar, nucleic acid, protein, or a combination of these substances. Subcutaneous biologics include vaccines, blood and its components, recombinant proteins, and others.

Subcutaneous biologics are the most advanced therapeutics used for the treatment of several diseases like cancer, diabetes, multiple sclerosis, psoriasis, and many more. Subcutaneous biologics are injected/infused so that the proteins are not digested or inactivated early. Whereas administration of subcutaneous biologics does not require highly skilled personnel as compared to intravenous biologics According to the International Diabetes Federation, 463 million suffered from diabetes in 2019 worldwide and is estimated to reach 578 million by 2030.

Segmentation of Subcutaneous Biologic Market Research

• By Indication :

  • Cancer
  • Crohn’s Disease
  • Cardiovascular Disorders
  • Diabetes
  • Multiple Sclerosis
  • Psoriasis
  • Rheumatoid Arthritis
  • Metabolic Disorders
  • Growth Hormone Deficiency

• By Delivery System :

  • Syringes
  • Wearable Injectors
  • Automatic Injectors
  • Implants
  • Pen Injectors

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa